Core Laboratories Inc.
CLB
$13.36
$0.181.33%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.45% | 6.98% | 0.09% | -0.32% | -4.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.45% | 6.98% | 0.09% | -0.32% | -4.67% |
| Cost of Revenue | 2.62% | 3.12% | -1.78% | 0.75% | -4.89% |
| Gross Profit | -18.21% | 24.75% | 7.35% | -4.30% | -3.72% |
| SG&A Expenses | 7.49% | 17.35% | 24.59% | 1.92% | 16.24% |
| Depreciation & Amortization | 1.26% | 0.11% | -2.23% | -2.65% | -3.28% |
| Other Operating Expenses | 51.59% | -61.99% | 62.76% | 83.77% | -286.70% |
| Total Operating Expenses | 3.50% | 3.98% | 0.59% | 1.39% | -3.31% |
| Operating Income | -74.77% | 39.88% | -3.43% | -13.68% | -21.12% |
| Income Before Tax | -155.32% | 14.53% | 9.48% | -1.71% | -64.74% |
| Income Tax Expenses | -114.38% | 98.58% | -19.97% | -47.05% | 5.31% |
| Earnings from Continuing Operations | -1,191.30% | -31.33% | 20.99% | 16.09% | -98.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 83.86% | -174.24% | -10.04% | 79.11% | 17.41% |
| Net Income | -412.34% | -33.16% | 21.23% | 17.76% | -104.78% |
| EBIT | -74.77% | 39.88% | -3.43% | -13.68% | -21.12% |
| EBITDA | -50.27% | 29.81% | -3.22% | -11.44% | -16.13% |
| EPS Basic | -418.18% | -31.61% | 22.97% | 18.49% | -104.80% |
| Normalized Basic EPS | -133.05% | 68.02% | -6.49% | -10.91% | -23.77% |
| EPS Diluted | -418.18% | -31.61% | 20.00% | 15.79% | -104.80% |
| Normalized Diluted EPS | -133.05% | 68.02% | -6.39% | -10.69% | -22.37% |
| Average Basic Shares Outstanding | -1.50% | -2.25% | -1.40% | -0.59% | -0.18% |
| Average Diluted Shares Outstanding | -1.50% | -2.25% | -1.55% | -0.79% | -1.95% |
| Dividend Per Share | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Payout Ratio | 0.81% | 0.49% | -0.18% | -0.15% | -21.95% |